Oncogenesis is a progressive process often involving collaboration between various oncogenes and tumor suppressors. To identify those genes that collaborate with oncogenic ras, we took advantage of the Tg.AC transgenic mouse, a line that harbors the v-Ha-ras transgene and spontaneously develops an array of malignant tumors. By crossing Tg.AC mice on an inbred FVB background to other inbred strains, F1 mice were created that could be analysed using genome wide, single nucleotide polymorphism (SNP) screens. Loss of heterozygosity (LOH) in tumors and tumor cell lines marked a somatic event, possibly the inactivation of tumor suppressor gene(s). LOH could also represent DNA damage, a sign of genomic instability in the pretransformed cell. Nonetheless, the screens showed no evidence of such generalized genomic instability. Instead, they revealed a single region of LOH on chromosome 4 that occurred via somatic recombination/gene conversion, generating a region of isoparental disomy. This LOH provided a clue that linked v-Ha-ras to the inactivation of the Ink4a locus in 25 of 32 tumor cell lines. This collaboration is seen regardless of tumor type or genetic background. In contrast, tumors that develop in bitransgenic mice bearing both the v-Ha-ras gene and a heterozygous mutant p53 allele tend to retain the Ink4a locus and instead lose the p53 wild-type allele. This suggests that different strategies can be selected to collaborate with v-Ha-ras in tumorigenesis.
Introduction
It has long been established that malignant transformation requires several genetic steps. The first of these can be replicated in transgenic mice by introducing a deleterious oncogene or by creating a null mutation in a tumor suppressor gene. To identify additional genetic requirements, we have bred mice to harbor two collaborating oncogenic transgenes or a single oncogenic transgene in conjunction with a null mutation in a tumor suppressor gene. The first experiment of this kind revealed in vivo collaboration between the v-Ha-ras and the c-myc transgene (Sinn et al., 1987) . Placing these two transgenes together in the germline led to a significant acceleration in the development of mammary tumors in the bitransgenics. Indeed, this approach was helpful in identifying numerous molecular pathways that could collaborate and accelerate tumorigenesis in vivo. However, collaboration as a consequence of breeding may not mimic the somatic events that occur spontaneously when tumor-prone mice develop malignancies. To pursue this issue further, we have bred tumor-prone transgenic mice (harboring a germline mutation) to normal mice of different inbred genetic backgrounds. The F1 offspring are heterozygous for every polymorphic marker in the parental lines and, as a consequence, regions of loss of heterozygosity (LOH) in tumor DNAs can be easily detected using single nucleotide polymorphism (SNP) screens. Regions of LOH detected in this way could reflect somatic mutations in a gene that, in combination with the oncogenic transgene, can promote tumor formation.
Indeed, LOH has been frequently observed in human tumors, some of which have led to the identification of important tumor suppressor genes. The discovery of the Rb gene is a case in point (Dryja et al., 1984) . For this approach to be successful, numerous informative markers are required. Using SNP analysis and genome-wide high-throughput screens (Moran et al., 2006) , we have searched for genes that collaborate with the ras oncogene in the context of a tumor-prone Tg.AC mouse. This mouse harbors the v-Ha-ras transgene and was generated on an inbred FVB background (Leder et al., 1990) . It is a particularly favorable cancer model, given that about 30% of all human tumors carry mutations in ras (Campbell and Der, 2004) .
Another very useful feature of the Tg.AC model (reviewed in Humble et al., 2005) is that virtually all of these mice develop benign papillomas and about 20% stochastically develop an array of malignant tumors, all of which express the v-Ha-ras transgene, and many resemble human neoplasms (Cardiff et al., 1993) .
It is apparent that despite the role that oncogenic ras plays in tumorigenesis, additional collaborating oncogenes or inactivation of tumor suppressor genes are required for malignant transformation. Among these are three genes encoded in the Ink4 (cdkn2) loci (Gil and Peters, 2006) . As shown in Figure 1a , the 5 0 Ink4b locus consists of two exons that encode a small 15-kDa protein, p15
Ink4b
. The 3 0 Ink4a locus encodes two distinct proteins, p16
Ink4a and p19
ARF . P16
Ink4a is assembled from three exons, 1a, 2 and 3, whereas p19 ARF consists of exons 1b, 2 and 3. Although the two proteins share exons 2 and 3, they use alternative reading frames (ARF) (Kamijo et al., 1997) . Thus, while the genes Ink4b p15 and Ink4a p16 are similar both in structure and function, p19 ARF shows no amino-acid homology to either p15
Ink4b or p16
Ink4a
. Inactivation of the above-noted Ink4 genes by deletion or promoter methylation has been observed in a high proportion of human and mouse cancers of different cell lineages (reviewed in Sharpless, 2005; Gil and Peters, 2006; Berger and Bardeesy, 2007) . Consequently, these genes have been shown to regulate two important tumor suppressor genes, pRb and p53 (Sherr and McCormick, 2002) , thus making the Ink4 loci critical to tumor suppression. P15 and p16, which are cyclin-dependent kinase CDK4 and CDK6 inhibitors, can control the level of pRb phosphorylation (Lukas et al., 1995) , whereas the major role of p19 is to maintain adequate levels of p53 (Kamijo et al., 1998; Pomerantz et al., 1998) . In addition, the Ink4a locus has also been implicated in promoting senescence in the face of aberrant proliferation, DNA damage or oncogenic stress, including that induced by oncognic ras (Serrano et al., 1997) . Thus, when active, the products of the Ink4 genes serve as a barrier to transformation (Ben-Porath and Weinberg, 2005; Campisi, 2005) .
In what follows, we describe a genome-wide SNP screen of F1 Tg.AC tumor cell lines derived from several different tumor types. The majority of these cell lines were found to carry a single region of LOH on chromosome 4, thus providing an important clue that links the oncogenic v-Ha-ras gene to homozygous deletions at the Ink4a and Ink4b loci. Knowing the involvement of these loci made it possible to test tumor cell lines that were generated on an inbred FVB genetic background (where SNP analysis is not otherwise applicable). Indeed, we found that in many of these cell lines and in primary tumors, the Ink4a and Ink4b loci are also inactivated. By contrast, tumor cell lines derived from bitransgenic Tg.AC/p53 þ /À mice seldom show inactivation of the Ink4 loci.
Results
Genome-wide SNP screening provided an efficient method for LOH identification in tumor cell lines To assess the status of the genome in mouse cell lines transformed in the presence of activated ras, 21 tumor cell lines were generated from spontaneous tumors developed in F1 Tg.AC transgenic mice. Among the relatively diverse tumor cell lines, ten were derived from skin tumors, seven from spleen histiocytomas, two from jaw tumors, one from a neck tumor and one from an enlarged lymph node. DNAs from F1 tumor cell lines and from corresponding normal tissues were subjected to high-throughput genotyping with a genome-wide panel of 394 SNPs. [12]
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[11] Figure 1 ). The remaining cell lines displayed only a single region of LOH on chromosome 4. In seven cell lines, the FVB alleles were lost, leaving the Balb, Spretus, C57BL/6J or C3H alleles (blue). In five other cell lines, the FVB alleles were retained, while the Balb/ cJ alleles were lost. The fact that in five of six FVB/Balb/ cJ cell lines the Balb alleles were lost suggests a bias for the loss of these alleles (Figure 2a ). It is also worth noting that our screen included one primary tumor (Figure 2a, FS6) . Reassuringly, both the tumor and the derived cell line displayed LOH on chromosome 4.
Metaphase chromosome analysis reveals an intact chromosome 4 Loss of heterozygosity in the distal regions of chromosome 4 could reflect deletions, which result in regions of hemizygosity. LOH across the entire length of chromosome 4 (Figure 2b ) could represent the loss of one chromosome 4 and the retention of the other. Alternatively, LOH could be the result of mitotic homologous recombination/gene conversion, where genetic exchange has occurred between homologous chromosomes. In this case, both alleles should be present and identical. To distinguish between the two mechanisms, metaphase chromosome spreads were analysed using fluorescent in situ hybridization with a probe positioned at the distal end of SPL6  FS6  FS6 CL  FS701 CL  FS13 CL  SP4 CL  SP14 CL  SP700 CL  FVB  SPR  SP  KID  FS1 CL  FS2 CL  FS4 CL  FVB  B6  SPL100  SP100 CL  LN100 CL  SP12  FS12 CL  SP16  SP16 CL  FS5 CL  J5  FVB  C3H This result rules out deletion as a mechanism for creating the observed LOH, and strongly suggests that mitotic recombination/gene conversion is the mechanism responsible for LOH in these tumor cell lines.
Tumor cell lines that displayed LOH on chromosome 4 had homozygous deletions at the Ink4 loci The finding of a single region of LOH in a diverse array of tumor cell lines strongly suggested a physiologic linkage between the v-Ha-ras transgene and the inactivation of a tumor suppressor located on chromosome 4. Logical candidates are the tumor suppressor loci Ink4b and Ink4a that map within the LOH boundaries (note the black arrows in Figure 2 ). Indeed, polymerase chain reaction (PCR) analysis reveals that all the cell lines displaying LOH suffer homozygous deletions in the Ink4a locus and many, but not all, display additional deletions in the adjacent Ink4b locus (Figures 1 and 4) . Interestingly, three tumor cell lines (FS12, FS5 and J5) that did not display LOH (Figure 2c ), did suffer homozygous deletions in the Ink4 loci (FS5 and J5 are shown in Figure 4b ). Evidently the mitotic events that resulted in homozygous deletions occurred between two adjacent SNP markers and, therefore, were not recognized by the SNP screen. We were also able to expand this finding to additional tumor cell lines developed on an FVB genetic background, which are not amenable to SNP analysis. As shown in Figure 1 , the size and extent of the deletions in the Ink4 loci varied among the different cell lines. The diagrammatic representation shown in Figure 1 was based on PCR reactions of individual exons; namely, Ink4b p15 exons 1 and 2, Ink4a p19 exon 1b, Ink4a p16 exon 1a and exons 2 and 3 that are shared by both Ink4a . Cell line LN520 (lane 9) failed to express all three Ink4 genes. In total, five of 12 tumor cell lines that retained Ink4a failed to express the locus (three are shown in Figure 4c ).
Ink4a
p16 and Ink4a p19 are simultaneously inactivated A summary of the various tumor cell lines with respect to tumor origin and Ink4a p16/p19 status is shown in Table 1 . 
Collaborating oncogenes
The pathology of the tumors was previously described in Cardiff et al. (1993) . Of 32 tumor cell lines, 25 (or 78%) showed inactivation of both Ink4a p16 and Ink4a
p19
. Of these, 20 suffered deletions. Despite the retention of these genes in five other tumor cell lines, they were not expressed. Methylation studies (Supplementary Figure 2) revealed partial promoter methylation in all five cell lines, while a fibrosarcoma cell line expressing the Ink4a . In Figure 5a , three fibrosarcoma cell lines (lanes 3-5) are shown, which express Ink4b p15 but not Ink4a p16/p19
. Sequence analysis of Ink4b p15 exons 1 and 2 in these three lines confirmed that they encoded the wildtype sequence (data not shown). Thus, it appears that for these tumor cell lines, the inactivation of Ink4b p15 was not required for transformation.
We next asked whether Ink4b p15 expression was elevated in cell lines that lost expression of Ink4a p16/p19 , which would suggest a feedback mechanism designed to compensate for Ink4a p16/p19 loss. To this end, quantitative real-time RT-PCR was performed. As can be seen in Figure 5b , Ink4b p15 is not upregulated in samples 3 and 4, the two cell lines that suffer inactivation of Ink4a p16/p19 . In fact, these cell lines show only moderate levels of Ink4b p15 expression, while cell lines 5 and 6, which expressed Ink4a p16/p19
, show high levels of expression. We suspect that this reflects the high variability of expression often seen in our tumor cell lines (Supplementary Figure   3) . Thus, the lack of an inverse correlation between the level of Ink4b p15 expression and the status of Ink4a p16/p19
is not consistent with a feedback mechanism.
Concordance between primary tumors and the corresponding tumor cell lines Analysing primary tumor DNAs by PCR is often hampered by the presence of contaminating normal tissue. As an alternative to primary tumors, we generated tumor cell lines where the absence of contamination would yield unambiguous results. Nonetheless, it is possible that while propagating in vitro, cells acquire new mutations not present in the tumors from which they were derived. It is, therefore, important to reconcile cell line findings with those of primary tumors. In contrast to DNA, contamination of tumor RNA by RNA from surrounding normal tissues is less likely to occur, since Ink4b p15 and Ink4a p16/p19
, which are often upregulated in tumors, are only minimally expressed in normal tissues (Gil and Peters, 2006) . For this reason, tumors and the corresponding cell lines were compared on the basis of RNA expression using RT-PCR.
Analyses of six cell lines and their corresponding primary tumors are shown in Figure 6 . We have previously shown that cell lines 1-3 express the Ink4 genes ( Figure 4c, lanes 8, 10 and 12 ). As expected, we also observed expression of these genes in the corresponding tumors. In contrast, the next three cell lines, two derived from skin fibrosarcomas (lanes 4 and 6) and one from a jaw tumor (lane 5) have previously been shown to undergo deletions in the Ink4 loci. Reassuringly, we found complete concordance between lack of expression in cell lines and lack of expression in the corresponding tumors. Thus, derived cell lines faithfully represented the primary tumors. (lanes 3 and 4), compared with a fibrosarcoma and squamous cell carcinoma that do express Ink4a p16/p19 (lanes 5 and 6). Error bars represent two real-time RT-PCR runs using triplicate samples. RT-PCR, reverse transcription-polymerase chain reaction.
Collaborating oncogenes A Leder et al
Tumor cell lines derived from Tg.AC/p53 þ /À bitransgenics tend to lose the p53 wild-type allele and retain the Ink4 genes We have shown that the inactivation of Ink4a p16/p19 and possibly Ink4b p15 collaborate with v-Ha-ras tumorigenesis in Tg.AC transgenic mice. Since the role of Ink4a p19 in tumor suppression is thought to depend to a large extent on the integrity of p53 (Sherr, 2006) , we wondered if the loss of p53 would abrogate the need for Ink4a p19 inactivation. With this question in mind, we analysed a panel of tumor cell lines derived from Tg.AC/p53 þ /À bitransgenic mice. In comparison to Tg.AC mice, the bitransgenics developed tumors at an accelerated rate. However, aside from thymomas that are more prevalent in bitransgenics, the spectrum of spontaneous tumors seen in Tg.AC and Tg.AC/p53 þ /À mice is quite similar (A Leder, unpublished observations).
To assess the status of the Ink4 loci and the wild-type p53 allele, PCR was performed on genomic DNAs of seven Tg.AC/p53 tumor cell lines. In contrast to Tg.AC, only one Tg.AC/p53 fibrosarcoma cell line displayed deletions of Ink4a p16/p19 (Figure 7a, lane 3) . The rest, generated from ameloblastoma, fibrosarcomas, thymoma, salivary and breast ( Figure 7a, lanes 4-9) , all retained the Ink4 genes. Interestingly, five of the six (lanes 5-9) lines have lost the p53 wild-type allele. Ameloblastoma A58 (lane 4) retained the Ink4 genes as well as the p53 wild-type allele. Expression analysis demonstrated that Tg.AC/p53 À/À cell lines that retained the Ink4 genes express them as well (Figure 7b) .
These results underscore a clear difference between Tg.AC and Tg.AC/p53 þ /À bitransgenics. While the majority of Tg.AC tumor cell lines displayed deletions and/or inactivation of Ink4a p16/p19 (Table 1) , only one of seven Tg.AC/p53 tumor cell lines suffered such a deletion. In addition, tumor cell lines (Figure 7a , lanes 5-9) that retain and express the Ink4 loci have lost the p53 wild-type allele, while the sole Tg.AC/p53 þ /À cell line that underwent Ink4a p16/p19 deletions, retained the p53 wild-type allele (Figure 7a, lane 3) . This suggests that the loss of p53 could abrogate the need for Ink4a p16/p19 inactivation in these cell lines. It also suggests that the loss of either Ink4a p16/p19 or p53 can collaborate with v-Ha-ras in tumorigenesis. Furthermore, it suggests the possibility that Tg.AC tumor cell lines that retain and express the Ink4 genes (Table 1 ) might have suffered mutations in p53. This prompted us to sequence p53 cDNA in these tumor cell lines; however, no mutations were found (data not shown), suggesting that, in addition to p53 and the Ink4 genes, other somatic events can collaborate with v-Ha-ras in the Tg.AC mouse model.
Ink4a
p16 and Ink4a p19 expression Tg.AC and Tg.AC/p53
À/À tumor cell lines that have been shown by RT-PCR to express Ink4a p16/p19 were further analysed by real-time RT-PCR and western blots. As seen in Supplementary Figure 3 , some cell lines show robust expression, whereas in others expression is hardly detectable. In one cell line, Ink4a p19 is highly expressed, while Ink4a p16 expression is very low, a discordance that suggests the two genes are independently regulated.
Discussion
Loss of heterozygosity seen in tumor DNAs generally represents somatic changes due to genomic instability, some of which is relevant to the transformation process. Judging by LOH, the Tg.AC tumor cell lines showed no evidence of genomic instability that occurred in pretransformed cells. Indeed, some cell lines displayed no LOH, while others (71%) displayed a unique region of LOH on chromosome 4, clearly a genetic event associated with transformation. The unique region of LOH in the F1 Tg.AC tumor cell lines provided a necessary starting point, which made it possible to identify the loss of Ink4a p16/p19 as a v-Ha-ras collaborator in multiple cell types (Table 1 ). The inactivation of Ink4a p16/p19 is likely to have occurred very early in the transformation process. Somatic events that occur later will affect some, but not all, of the tumor's cells and, therefore, will not be seen as LOH in our PCR-based assay. 
Collaborating oncogenes A Leder et al
Screening for LOH is not always straightforward. For example, our genome-wide SNP screen of F1 p53-deficient tumors revealed multiple chromosomes with LOH. This made the task of identifying collaborators in F1 p53-deficient tumors much more difficult (data not shown).
While oncogenic ras promotes aberrant proliferation, it also activates Ink4a p16/p19
, which in turn induces senescence (Serrano et al., 1997; Lin and Lowe, 2001; KellySpratt et al., 2004) . Upon inactivation of Ink4a p16/p19 , the balance is shifted toward uncontrolled proliferation and, eventually, transformation. Indeed, collaboration between oncogenic ras and the inactivation of Ink4a p16/p19 , which is found in the majority of our tumor cell lines, fits well with this model. This association between oncogenic ras and Ink4a p16/p19 inactivation has been described for tumors in both humans (Guan et al., 1999; Tannapfel et al., 2000) and mice (Linardopoulos et al., 1995; Chin et al., 1997; Lin and Lowe, 2001; Uhrbom et al., 2002; Aguirre et al., 2003) . However, the extent of the linkage that we have observed (78%) is surprising, especially since these spontaneous tumors were of several different tissue origins and were developed in mice of different genetic backgrounds. This suggests that v-Ha-ras, to a large degree, predetermines the subsequent step in the multistep process that ultimately leads to cancer. It remains to be seen how extensive the linkage is in human malignancy.
Targeted deletion in the mouse suggests that the three Ink4 genes play a role in tumor suppression. While a null mutation of each alone displays a rather weak tumor phenotype, mice with targeted deletions of both Ink4a p16 and Ink4a p19 are more profoundly affected (reviewed in Sharpless, 2005; Gil and Peters, 2006; Berger and Bardeesy, 2007) . Further, it has recently been shown that mice deficient for Ink4b p15 as well as Ink4a p16/p19 are extremely tumor prone (Krimpenfort et al., 2007) ; lanes 3-7 contain tumor cell lines retaining the Ink4 genes; lanes 3 and 4 are fibrosarcomas FS16 and FS17; lanes 5 and 6 are thymomas T14 and T27 and lane 7 is salivary tumor S1. b-actin RT-PCR was performed as a control. For each sample, þ /À refers to cDNA made with or without reverse transcriptase. PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction.

Ink4a
p19 regulates the p53 pathway, it appears that interruption of both is required for v-Ha-ras-induced tumorigenesis. One could argue that the unusual genomic structure of the Ink4a locus (Figure 1a ) might account for the observed co-inactivation. Although possible, this seems less likely, especially since Ink4a p16 and Ink4a p19 have been shown to be independently regulated in some settings (reviewed in Sharpless, 2005; Gil and Peters, 2006; Berger and Bardeesy, 2007) .
We have also shown that inactivation of p53 alone can collaborate with v-Ha-ras in Tg.AC/p53 þ /À bitransgenic mice. This implicates the linear signal transduction pathway that links p53 and pRB, possibly through the cyclinE/cdk2 inhibitor, p21 (Beausejour et al., 2003; Ben-Porath and Weinberg, 2005 , which required two somatic events, was selected for, even though loss of the p53 wild-type allele would have required only one. This supports the notion that Ink4a p16/p19 inactivation is the preferred somatic event in v-Ha-ras tumorigenesis.
Materials and methods
Mice
Tumor-prone Tg.AC FVB mice were crossed to Balb/cJ, Spretus/ Ei, C57BL/6J and C3H/HeJ mice to generate F1 FVB/X mice. Tg.AC/p53 þ /À bigenic mice were generated by crossing Tg.AC FVB and p53-null mice (Donehower et al., 1992) , which were first bred from 129 to FVB for seven generations.
Tumor cell lines
Tumor samples were cultured in Dulbecco's Modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma, St Louis, MO, USA) and 100 U penicillin G with 100 mg streptomycin sulfate/ml (Invitrogen) at 37C and 7.5% CO 2 .
Nucleic acid isolation and cDNA synthesis DNA from tumors, tumor cell lines and normal tissues was isolated using proteinase-K digestion (Leder et al., 1997) . Total RNA was isolated using cesium chloride gradient purification (Chirgwin et al., 1979) . cDNA was prepared using the oligo-dT method in the ProtoScript First-Strand cDNA Synthesis kit (New England Biolabs, Ipswich, MA, USA).
SNP analysis
DNA from tumor cell lines and normal tissue controls were genotyped with a panel of 394 SNPs as described in Moran et al. (2006) . SNPs that are both informative between the background strains and heterozygous in the normal tissue controls were considered in the analyses. Genotype calls for all SNPs were made by comparing allele ratios using the SpectoTYPER-RT software (Sequenom, San Diego, CA, USA) or manually.
Genotyping of tumor cohorts
Tg.AC and Tg.AC/p53 þ /À mice were genotyped by Southern blot analysis (Leder et al., 1990) . P53 PCR genotyping was performed using the following primers:
P531B The wild-type p53 band is B325 bp and the p53-null band is B250 bp. DNA was denatured at 951 C for 5 min, followed by 40 cycles of 941 C for 30 s, 601 C for 1 min and 721 C for 2 min, with a final extension at 721 C for 10 min.
PCR for Ink4 loci DNA was denatured at 941 C for 2 min, followed by 30 cycles of 941 C for 30 s, 621 C for 45 s, and 681 C for 1 min, with a final extension at 681 C for 8 min. PCR was performed using Advantage-GC cDNA Polymerase Mix (Clontech, Mountain View, CA, USA). Refer to Supplementary Table 1 in Supplementary Data for a summary of the primers and expected amplicon sizes. and RBS17R, 5 0 -TGGTGTCGGGATCCACCTCAATGA-3 0 ; they amplify cDNA encoding a constitutively expressed ribosomal protein, and were used as control primers. For conditions, refer to Supplementary Methods.
RT-PCR
